CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab

Autoimmune disease is a well-recognized complication of alemtuzumab therapy in MS; however, the risk of subsequent malignancy is another important consideration in this highly efficacious therapy. Here, we report a fatal atypical T-cell hematologic disorder.

Source: Neurology Clinical Practice - June 9, 2019 Category: Neurology Authors: Khan, M., Ney, D. E., Kleinschmidt-DeMasters, B. K., Horton, L., Alvarez, E., Piquet, A. L. Tags: All Immunology, Primary brain tumor, All Demyelinating disease (CNS), Multiple sclerosis Case Source Type: research